Kurzfassung

A phase III, RANDOMIZED, open-label, multicenter
study evaluating the efficacy AND safety of adjuvant giredestrant compared with physician's choice of adjuvant Endocrine MONotherapy in patients with ESTROGEN RECEPTOR-POSITIVe, her2‑negative EARLY breast cancer